Jaing, T.-H. and Wang, Y.-L. (2020) “Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: ‘Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications’”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2026.301889.